Calabrese LH, et al. - In a subset of patients with rheumatoid arthritis (RA) who received live zoster vaccine (LZV) before tofacitinib ± methotrexate (MTX), or adalimumab + MTX, researchers examined herpes zoster (HZ) rates and safety of LZV, in ORAL Strategy (a 1-year, Phase 3b/4, randomized triple-dummy, active-comparator-controlled study). LZV was administered to 216/1146 patients (18.8%; aged ≥50 years) 28 days before initiating study treatment. The patients showed good tolerability to LZV. Treatment groups and vaccinated vs non-vaccinated patients had generally similar HZ incidence rates. However, ORAL Strategy was not powered for comparisons between vaccinated and non-vaccinated patients as vaccination was evident in <20% of all patients. Furthermore, the efficacy of LZV was noted only in around 50% of individuals.